Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial

Brouwer, Annelies; van Raalte, Daniël H.; Diamant, Michaela; Rutters, Femke; van Someren, Eus J. W.; Snoek, Frank J.; Beekman, Aartjan T. F.; Bremmer, Marijke A.
July 2015
BMC Psychiatry;2015, Vol. 15 Issue 1, p1
Academic Journal
Background: Major depression and type 2 diabetes often co-occur. Novel treatment strategies for depression in type 2 diabetes patients are warranted, as depression in type 2 diabetes patients is associated with poor prognosis and treatment results. Major depression and concurrent sleep disorders have been related to disturbances of the biological clock. The biological clock is also involved in regulation of glucose metabolism by modulating peripheral insulin sensitivity. Light therapy has been shown to be an effective antidepressant that 'resets' the biological clock. We here describe the protocol of a study that evaluates the hypothesis that light therapy improves mood as well as insulin sensitivity in patients with a major depressive episode and type 2 diabetes. Methods/design: This study is a randomised, double-blind, parallel-arm trial in 98 participants with type 2 diabetes and a major depressive episode, according to DSM-IV criteria. We will assess whether light therapy improves depressive symptoms and insulin sensitivity, our primary outcome measures, and additionally investigate whether these effects are mediated by restoration of the circadian rhythmicity, as measured by sleep and hypothalamic-pituitaryadrenal axis activity. Participants will be randomly allocated to a bright white-yellowish light condition or dim green light condition. Participants will undergo light therapy for half an hour every morning for 4 weeks at home. At several time points, namely before the start of light therapy, during light therapy, after completion of 4 weeks of light therapy and after 4 weeks follow-up, several psychometrical, psychophysiological and glucometabolic measures will be performed. Discussion: If light therapy effectively improves mood and insulin sensitivity in type 2 diabetes patients with a major depressive episode, light therapy may be a valuable patient friendly addition to the currently available treatment strategies. Additionally, if our data support the role of restoration of circadian rhythmicity, such an observation may guide further development of chronobiological treatment strategies in this patient population.


Related Articles

  • Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial. An Pan; Jianqin Sun; Yanqiu Chen; Xingwang Ye; Huaixing Li; Zhijie Yu; Yanfang Wang; Wenjia Gu; Xinyi Zhang; Xiafei Chen; Demark-Wahnefried, Wendy; Yong Liu; Xu Lin // PLoS Clinical Trials;Nov2007, Vol. 4 Issue 11, p1 

    Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin...

  • Effect of Folic Acid Supplementation on Indices of Glycemic Control, Insulin Resistance and Lipid Profile in Patients With Type 2 Diabetes Mellitus. Aghamohammadi khiavi, V.; Pourghassem Gargari, B.; Aliasgharzadeh, A. // Iranian Journal of Endocrinology & Metabolism;Nov2011, Vol. 13 Issue 4, p424 

    Introduction: This study was performed to determine the effects of supplementation of folate on indices of glycemic control, insulin resistance and lipid profile in in men with type 2 diabetes, under metformin (at least 1500mg daily) treatment. Materials and Methods: This was a double-blind...

  • Prevention of Diabetes With Pioglitazone in ACT NOW. DeFronzo, Ralph A.; Tripathy, Devjit; Schwenke, Dawn C.; Banerji, MaryAnn; Bray, George A.; Buchanan, Thomas A.; Clement, Stephen C.; Gastaldelli, Amalia; Henry, Robert R.; Kitabchi, Abbas E.; Mudaliar, Sunder; Ratner, Robert E.; Stentz, Frankie B.; Musi, Nicolas; Reaven, Peter D. // Diabetes;Nov2013, Vol. 62 Issue 11, p3920 

    We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45...

  • Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. Oster, Gerry; Sullivan, Sean D.; Dalal, Mehul R.; Kazemi, Mahmood R.; Rojeski, Maria; Wysham, Carol H.; Sung, Jennifer; Johnstone, Bryan; Cali, Anna M.G.; Wei, L.J.; Traylor, Louise; Anhalt, Henry; Hull, Michelle; Van Vleet, John; Meneghini, Luigi F. // Postgraduate Medicine;Nov2016, Vol. 128 Issue 8, p731 

    Objective: This study aims to compare the effectiveness of insulin glargine 300 U/mL (Gla-300) with its accompanying patient support program with that of other basal insulin and available patient support programs in patients with type 2 diabetes (T2D) in a real-world setting in...

  • Degludec, a New Ultra-long-acting Basal Insulin for Diabetes.  // Neurology Alert;Jul2012 Clinical Briefs in, p13 

    The article discusses a controlled trial in type 2 diabetic patients to compare degludec with glargine as part of a basal-bolus regimen, referencing a study by A. J. Garber and colleagues that was published in a 2012 issue of the "Lancet."

  • The influence of initiating insulin therapy on revealing of psychic disturbances in patients suffering from type 2 diabetes. Chmiel-Perzyńska, Iwona; Perzyński, Adam; Derkacz, Marek // Experimental & Clinical Diabetology / Diabetologia Doswiadczalna;2010, Vol. 10 Issue 1, p41 

    Background. The aim of this study was to assess the influence of starting insulin therapy in patients with type 2 diabetes on revealing psychic disturbances. Methods. The study was conducted on 54 outpatients suffering from type 2 diabetes, examined after 3 to 6 weeks from the start of insulin...

  • Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials. Lebovitz, Harold E.; Kreider, Margaret; Freed, Martin I. // Diabetes Care;May2002, Vol. 25 Issue 5, p815 

    Presents a study that assessed whether the idiosyncratic liver toxicity reported with troglitazone is molecule-specific or a thiazolidinedione class effect. Analysis of data obtained from rosiglitazone monotherapy; Baseline demographic and clinical characteristics; Effectiveness of...

  • The Combined Effect of Triple Therapy With Rosiglitazone, Metformin, and Insulin Aspart in Type 2 Diabetic Patients. Poulsen, Mikael KÆr; Henriksen, Jan Erik; Hother-Nielsen, Ole; Beck-Nielsen, Henning // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3273 

    OBJECTIVE — Type 2 diabetes is caused by reduced insulin secretion and insulin resistance in skeletal muscle and liver. We tested the combination therapy with insulin aspart, rosiglitazone, and metformin with the purpose of treating all three defects in order to test the hypothesis that...

  • Erratum to: Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. Ortega, Francisco; Mercader, Josep; Moreno-Navarrete, José; Sabater, Mónica; Pueyo, Neus; Valdés, Sergio; Ruiz, Bartomeu; Luche, Elodie; Serino, Matteo; Naon, Deborah; Ricart, Wifredo; Botas, Patricia; Delgado, Elias; Burcelin, Remy; Frühbeck, Gema; Bosch, Fatima; Mingrone, Gertrude; Zorzano, Antonio; Fernández-Real, José // Journal of Molecular Medicine;Apr2013, Vol. 91 Issue 4, p535 

    A correction to the article "Targeting the Association of Calgranulin B (S100A9) With Insulin Resistance and Type 2 Diabetes" that was published in the March 8, 2013 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics